427. Unveiling Distinct Representations of P3a in Schizophrenia Through MMN-P3a and Three-Stimulus Auditory Oddball Paradigms
The P3a component of event-related potentials (ERP), a potential biomarker for schizophrenia (SZ), shares similar scalp distributions and time windows when elicited by different paradigms. Although reported as impaired in SZ, it remains unknown whether P3a responses from various paradigms reflect the same underlying neural processes and correlate with cognitive performances and are interchangeable. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Chenguang Jiang, Jun Wang, Jen Q. Pan, Mei-Hua Hall Source Type: research
426. Functional Characterization of De Novo Damaging Mutations in Patients With Sporadic Schizophrenia Using CRISPRi in iPSCs
Schizophrenia is a devastating neuropsychiatric disorder, with very strong contribution of genetic factors, both inherited and de novo. Functional characterization of rare damaging mutations in patients holds promise for uncovering disease mechanisms. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Anna Sunshine, Suleyman Gulsuner, Tom Walsh, Mary-Claire King, Jon McClellan Source Type: research
423. Biomarkers of Auditory Information Processing and Neural Synchrony Predict Targeted Cognitive Training Exercise Completion in a Transdiagnostic Population
Mismatch negativity (MMN), P3a, auditory steady state response (ASSR) gamma evoked power (EP) and inter-trial phase coherence (ITC) predict gains from a full course of auditory-based targeted cognitive training (TCT) in schizophrenia (SZ), but it is not known if they effectively predict gains in transdiagnostic cohorts. We tested whether these biomarkers predicted the number of levels of the TCT exercise "Sound Sweeps" completed during a one-hour initial TCT exposure, which is representative of a typical ∼30 h TCT training program. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Yash Joshi, Christopher Gonzalez, Daniel Zoleikhaeian, Juan Molina, Bethany Nordberg, Francesca Li, Jenny Min Din, Jessica Minhas, Jo Talledo, Joyce Sprock, Neal Swerdlow, Gregory Light Source Type: research
422. Schizophrenia Patient Cluster Identification and Characterization
In this study, we applied cluster analysis to identify schizophrenia subtypes. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Xinghong Tang, Rui Lu, Xueying Lyu, Lina Yang, Antonio Parrado, Francisco Talamas, Wayne Drevets, Gayle Wittenberg, Qingqin Li Source Type: research
421. Associated Impairments in Neurocognition and Psychophysiological Biomarkers for Psychosis Risk in Individuals With 22q11.2 Deletion Syndrome
22q11DS is a robust genetic predictor of schizophrenia (SCZ) and other psychiatric illnesses: nearly 30% of individuals develop SCZ. Understanding the relationship of cognition and psychophysiological variables could lead to a greater understanding of circuit-based abnormal functioning in 22q11DS and SCZ. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Gabrielle Ruban, David Parker, Sidney Imes, Brett Henshey, Nicholas Massa, Grace Lee, Bruce Cuthbert, Opal Ousley, Elaine Walker, Joseph F. Cubells, Erica Duncan Source Type: research
420. Reshaping Hippocampal Input-Prefrontal Interneuron Interactions in Wildtype and 22q12 Deletion-Relevant Model Mice
Functional connectivity between rodent ventral hippocampus (vHPC) and medial prefrontal cortex (mPFC) supports many cognitive functions and is disrupted in the Df(16)A+/ – mouse model of the schizophrenia-predisposing 22q11.2 deletion syndrome. Inhibition of vHPC inputs to mPFC or somatostatin-expressing interneurons (SST-INs) in wildtype mice induces vHPC-mPFC dysconnectivity and cognitive deficits that mimic phenotypes observed in Df(16)A+/– mice. These findin gs suggest that interactions between vHPC inputs and SST-INs play a privileged role in SWM, and that strengthening their connectivity may counteract 22q11.2-re...
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Erik Vaughan, Thomas Clarity, Shana Silverstein, Meena Deshpande, Rachel Mikofsky, Maxym Myroshnychenko, Marjorie Sapphire Bowen-Kauth, Madeline Hsiang, Joshua Gordon, Joshua Gordon, David Kupferschmidt Source Type: research
419. Scaling of Smaller Pyramidal Neuron Size and Lower Energy Production in Schizophrenia
Dorsolateral prefrontal cortex (DLPFC) dysfunction in schizophrenia appears to reflect alterations in layer 3 pyramidal neurons (L3PNs) that include smaller cell bodies and lower expression of mitochondrial energy production genes. However, somal size studies have used biased strategies for identifying L3PNs, energy production markers have not been assessed in individual L3PNs, and the relationship between these measures has not been assessed in the same L3PNs. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Kirsten Schoonover, Nora Miller, Kenneth Fish, David Lewis Source Type: research
416. Childhood Trauma and Suicidal Ideation and Behavior in Schizophrenia Spectrum Disorders
We examined the role of childhood trauma in SIB in a sample of people with schizophrenia spectrum disorders. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Matthew Hoptman, Kathryn T. Evans, Zamfira Parincu, Dan V. Iosifescu Source Type: research
415. Interest in Clinical Trials Involving Experimental Medication Among People With Schizophrenia
Among people with schizophrenia interested in research participation, only a subset of individuals specify interest in studies involving experimental medication (clinical trials). For efficient recruitment, it would be beneficial to identify factors associated with people with schizophrenia who are more likely to express interest in clinical trials. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Tala Berro, Megan Mayer, Joohyun Yoon, Joshua Kantrowitz Source Type: research
414. Understanding the Role of Muscarinic M1 and M4 Receptors in Neural Circuits That Modulate Negative Symptoms of Schizophrenia
Currently available antipsychotics target dopamine receptors and ameliorate positive symptoms but may not improve negative and cognitive symptoms. Recent preclinical and clinical research suggests that targeting muscarinic acetylcholine (mACh) M1 and M4 receptor subtypes could provide symptomatic relief across symptom domains. The M1/M4 agonist KarXT has shown clinical efficacy as a broad-spectrum monotherapy for total, positive, and negative symptoms (NS) in participants experiencing acute psychosis in clinical trials; a post hoc analysis of participants with prominent NS indicated KarXT-associated NS improvements were in...
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Samantha E. Yohn, William P. Horan, Stephen K. Brannan, Steven M. Paul Source Type: research
412. Efficacy of Karxt on Negative Symptoms in Acute Schizophrenia: A Post Hoc Analysis of Participants With Prominent Negative Symptoms
KarXT, an M1 /M4 preferring central muscarinic receptor agonist, has shown efficacy for the treatment of PANSS total and positive symptoms in acute schizophrenia across three phase 2/3 trials. It is possible that KarXT may also have a direct treatment benefit for negative symptoms (NS) that is not secondary to positive symptom improvements. Post hoc analyses explored the possible efficacy of KarXT in a subgroup of participants with moderate/severe NS and no predominance of positive symptoms. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: William Horan, Amy Claxton, Steven D. Targum, Samantha E. Yohn, Inder Kaul, Sharon Sawchak, Andrew C. Miller, Steven M. Paul, Stephen K. Brannan Source Type: research
411. Investigating the Effects of Adjunctive Transcranial Direct Current Stimulation on Treatment Adherence in Schizophrenia: Study Progress
This study seeks to explore for the first time the effects of transcranial direct current stimulation (tDCS) as an adjunctive treatment to improve antipsychotic medication adherence in patients with schizophrenia. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Jianmeng Song, Julia Kim, Yasaman Kambari, Aron Amaev, Fumihiko Ueno, Edgardo Torres Carmona, Ali Abdolizadeh, Teruki Koizumi, Vincenzo De Luca, Daniel M. Blumberger, Gary Remington, Bruce Pollock, Ariel Graff-Guerrero, Philip Gerretsen Source Type: research
410. Maternal Immune Activation Alters Mitochondrial Membrane Potential in Offspring in Vivo
Maternal immune activation (MIA) during pregnancy is a risk factor for schizophrenia. In rodents, MIA can be modeled using polyinosinic-polycytidylic acid (Poly I:C), a viral mimetic that produces an inflammatory response in the dam and fetuses. MIA also produces a variety of behavioral changes associated with schizophrenia, including social interaction deficits. Immune activation is known to disrupt mitochondrial function and impair ATP production. Therefore, in the current experiments, we tested the hypothesis that MIA alters mitochondrial membrane potential ( ΔΨm), the ability to maintain the electrochemical gradient ...
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Jennifer Donegan, Arkadiy Bazhin, Ekaterina Solodnikova, Elena Goun Source Type: research
409. Cortico-Thalamic Structural Co-Variation Networks are Related to Familial Risk for Schizophrenia in the Context of Lower Nuclei Volume Estimates in Patients: An ENIGMA Study
Thalamic and cortical structural differences have been reported in individuals with schizophrenia (SCZ) though studies on familial risk for schizophrenia (FHR) show mixed results. Most studies have often examined the thalamus as a whole, and as a single region-of-interest. We, therefore, investigated whether local and global thalamic-related structural alterations (respectively, volume of thalamic subdivisions and thalamo-cortical/cortico-cortical structural co-variation) vary as a function of risk for schizophrenia. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Annalisa Lella, Linda A. Antonucci, Daniel R. Weinberger, David C. Glahn, Kang Sim, Oliver Gruber, Young-Chul Chung, Gisela Sugranyes, Edith Pomarol Clote, Machteld Marcelis, Tilo Kircher, Tamsyn E. Van Rheenen, Scott R. Sponheim, Udo Dannlowski, Felice I Source Type: research
406. Cerebellar Dysconnectivity in Schizophrenia – Bipolar Disorder Spectrum is Associated With Cognitive and Clinical Variables
In this study, we examined cerebellar FC changes in the SCZ –BD spectrum and their association with cognitive and clinical variables. (Source: Biological Psychiatry)
Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Giulia Cattarinussi, Annabella Di Giorgio, Fabio Sambataro Source Type: research
